At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Apr 21, 2026 at 07:30 ET
Corvus Pharmaceuticals will host an investor meeting on May 14, 2026, to highlight new Phase 1 clinical data for soquelitinib in atopic dermatitis, including late-breaking data on drug-free remissions, presented at the Society for Investigative Dermatology meeting. The company will report Q1 2026 financial results on May 7 but will not hold a conference call.
- Investor and analyst meeting scheduled for May 14, 2026, to discuss soquelitinib Phase 1 data from the SID Annual Meeting.
- Two oral presentations at SID include a late-breaking session on drug-free remissions with soquelitinib.
- Phase 1 trial data is from a randomized, blinded, placebo-controlled study in moderate-to-severe atopic dermatitis.
- Company to release Q1 2026 financial results on May 7, 2026, without a conference call or webcast.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access